Paris Saponins enhance radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line by inducing apoptosis and G2/M cell cycle phase arrest

Molecular Medicine Reports

Volumn 13, Issue 3, 2016, Pages 2878-2884

  Zhao, Peng Jun ^a   Song, Shui Chuan ^b   Du, Lei Wen ^b   Zhou, Guo Hua ^c   Ma, Sheng Lin ^d   Li, Jin Hui ^e   Feng, Jian Guo ^a   Zhu, Xin Hai ^f   Jiang, Hao ^f  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b 117 Hospital of People's Liberation Army   (China)

^c Anji People's Hospital   (China)

^d HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^e THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f ZHEJIANG HOSPITAL   (China)

Author keywords

Apoptosis; Gefitinib resistance; Paris Saponin; Radiosensitivity

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; GEFITINIB; PARIS SAPONIN II; PARIS SAPONIN VI; PARIS SAPONIN VII; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; SAPONIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; BCL2 PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DIOSGENIN; FORMOSANIN C; QUINAZOLINE DERIVATIVE; RADIOSENSITIZING AGENT;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; LUNG ADENOCARCINOMA; M PHASE CELL CYCLE CHECKPOINT; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; HUMAN; LUNG NEOPLASMS; METABOLISM; RADIATION TOLERANCE; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DIOSGENIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINAZOLINES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SAPONINS;

EID: 84958720885     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.4865     Document Type: Article

References (45)

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
2. Sordella R, Bell DW, Haber DA and Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167, 2004.
3. Workman P: Altered states: Selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 10: 47-51, 2004.
4. Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, et al: The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung cancer 75: 161-166, 2012.
5. Langer CJ: Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: Is afatinib better or simply newer? J Clin Oncol 31: 3303-3306, 2013.
6. Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, Zakowski MF, Kris MG and Ladanyi M: EGFR exon 20 insertion mutations in lung adenocarcinomas: Prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 12: 220-229, 2013.
7. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73, 2005.
8. Gainor JF and Shaw AT: Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 31: 3987-3996, 2013.
9. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19: 2240-2247, 2013.
10. Lutz ST, Jones J and Chow E: Role of radiation therapy in palliative care of the patient with cancer. J Clin Oncol 32: 2913-2919, 2014.
11. Socinski MA, Rosenman JG, Halle J, Schell MJ, Lin Y, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, et al: Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIA/B nonsmall cell lung carcinoma: A modified phase I/II trial. Cancer 92: 1213-1223, 2001.
12. Santana-Davila R, Devisetty K, Szabo A, Sparapani R, Arce-Lara C, Gore EM, Moran A, Williams CD, Kelley MJ and Whittle J: Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. J Clin Oncol 33: 567-574, 2015.
13. Jiang H, Zhao P, Feng J, Su D and Ma S: Effect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line. Oncol Lett 7: 2059-2064, 2014.
14. Yan L, Gao W, Zhang Y and Wang Y: A new phenylpropanoid glycosides from Paris polyphylla var. yunnanensis. Fitoterapia 79: 306-307, 2008.
15. Negi JS, Bisht VK, Bhandari AK, Bhatt VP, Singh P and Singh N: Paris polyphylla: Chemical and biological prospectives. Anticancer Agents Med Chem 14: 833-839, 2014.
16. He H, Zheng L, Sun YP, Zhang GW and Yue ZG: Steroidal saponins from Paris polyphylla suppress adhesion, migration and invasion of human lung cancer A549 cells via down-regulating MMP-2 and MMP-9. Asian Pac J Cancer Prev 15: 10911-10916, 2014.
17. Cheng ZX, Liu BR, Qian XP, Ding YT, Hu WJ, Sun J and Yu LX: Proteomic analysis of anti-tumor effects by Rhizoma Paridis total saponin treatment in HepG2 cells. J Ethnopharmacol 120: 129-137, 2008.
18. Man S, Gao W, Zhang Y, Yan L, Ma C, Liu C and Huang L: Anti-tumor and antimetastatic activities of Rhizoma Paridis saponins. Steroids 74: 1051-1056, 2009.
19. Ma DD, Lu HX, Xu LS and Xiao W: Polyphyllin D exerts potent anti-tumour effects on Lewis cancer cells under hypoxic conditions. J Int Med Res 37: 631-640, 2009.
20. Shuli M, Wenyuan G, Yanjun Z, Chaoyi M, Liu Y and Yiwen L: Paridis saponins inhibiting carcinoma growth and metastasis in vitro and in vivo. Arch Pharm Res 34: 43-50, 2011.
21. GuangLie C, WeiShi G, GaiLing H and JianPing C: Effect of Paris saponin on antitumor and immune function in U14 tumor-bearing mice. Afr J Tradit Complement Altern Med 10: 503-507, 2013.
22. Wen F, Yin H, Chen C, Liu X, Xue D, Chen T, He J and Zhang H: Chemical characteristics of saponins from Paris fargesii var. brevipetala and cytotoxic activity of its main ingredient, Paris saponin H. Fitoterapia 83: 627-635, 2012.
23. Zhao Y, Kang LP, Liu YX, Liang YG, Tan DW, Yu ZY, Cong YW and Ma BP: Steroidal saponins from the rhizome of Paris polyphylla and their cytotoxic activities. Planta Med 75: 356-363, 2009.
24. Yan LL, Zhang YJ, Gao WY, Man SL and Wang Y: In vitro and in vivo anticancer activity of steroid saponins of Paris polyphylla var. yunnanensis. Exp Oncol 31: 27-32, 2009.
25. He H, Sun YP, Zheng L and Yue ZG: Steroidal saponins from Paris polyphylla induce apoptotic cell death and autophagy in A549 human lung cancer cells. Asian Pac J Cancer Prev 16: 1169-1173, 2015.
26. Jiang H, Zhao PJ, Su D, Feng J and Ma SL: Paris saponin I induces apoptosis via increasing the Bax/Bcl-2 ratio and caspase-3 expression in gefitinib-resistant non-small cell lung cancer in vitro and in vivo. Mol Med Rep 9: 2265-2272, 2014.
27. Xiao X, Bai P, Bui Nguyen TM, Xiao J, Liu S, Yang G, Hu L, Chen X, Zhang X, Liu J and Wang H: The antitumoral effect of Paris Saponin I associated with the induction of apoptosis through the mitochondrial pathway. Mol Cancer Ther 8: 1179-1188, 2009.
28. Xiao M, Dai X, He X, Zhou R, Zhang B, Hu G, Huang Z and Fan X: Paris saponin I induces G2/M cell cycle arrest and apoptosis in human gastric carcinoma SGC7901 cells. J Huazhong Univ Sci Technolog Med Sci 31: 768-772, 2011.
29. Zhao P, Jiang H, Su D, Feng J, Ma S and Zhu X: Inhibition of cell proliferation by mild hyperthermia at 43°C with Paris Saponin I in the lung adenocarcinoma cell line PC-9. Mol Med Rep 11: 327-332, 2015.
30. Xiao X, Yang M, Xiao J, Zou J, Huang Q, Yang K, Zhang B, Yang F, Liu S, Wang H and Bai P: Paris Saponin II suppresses the growth of human ovarian cancer xenografts via modulating VEGF-mediated angiogenesis and tumor cell migration. Cancer Chemother Pharmacol 73: 807-818, 2014.
31. Xiao X, Zou J, Bui-Nguyen TM, Bai P, Gao L, Liu J, Liu S, Xiao J, Chen X, Zhang X and Wang H: Paris saponin II of Rhizoma Paridis - a novel inducer of apoptosis in human ovarian cancer cells. Biosci Trends 6: 201-211, 2012.
32. Li Y, Sun Y, Fan L, Zhang F, Meng J, Han J, Guo X, Zhang D, Zhang R, Yue Z and Mei Q: Paris saponin VII inhibits growth of colorectal cancer cells through Ras signaling pathway. Biochem Pharmacol 88: 150-157, 2014.
33. Zhang W, Zhang D, Ma X, Liu Z, Li F and Wu D: Paris saponin VII suppressed the growth of human cervical cancer Hela cells. Eur J Med Res 19: 41, 2014.
34. Fan L, Li Y, Sun Y, Yue Z, Meng J, Zhang X, Zhang R, Zhang D, Zhang F and Mei Q: Paris saponin VII inhibits metastasis by modulating matrix metalloproteinases in colorectal cancer cells. Mol Med Rep 11: 705-711, 2015.
35. Li Y, Fan L, Sun Y, Miao X, Zhang F, Meng J, Han J, Zhang D, Zhang R, Yue Z and Mei Q: Paris saponin VII from trillium tschonoskii reverses multidrug resistance of adriamycin-resistant MCF-7/ADR cells via P-glycoprotein inhibition and apoptosis augmentation. J Ethnopharmacol 154: 728-734, 2014.
36. Ji Y, Ma SL, Zhang YP, Tang JJ, Wu YM and Lu YJ: Combined treatment with TNF-α/gefitinib alleviates the resistance to gefitinib in PC-9 cells. Anticancer Drugs 20: 832-837, 2009.
37. Deckbar D, Jeggo PA and Löbrich M: Understanding the limitations of radiation-induced cell cycle checkpoints. Crit Rev Biochem Mol Biol 46: 271-283, 2011.
38. McIlwain DR, Berger T and Mak TW: Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol 5: a008656, 2013.
39. Hu Q, Peng J, Liu W, He X, Cui L, Chen X, Yang M, Liu H, Liu S and Wang H: Elevated cleaved caspase-3 is associated with shortened overall survival in several cancer types. Int J Clin Exp Pathol 7: 5057-5070, 2014.
40. Dhar R, Persaud SD, Mireles JR and Basu A: Proteolytic cleavage of p70 ribosomal S6 kinase by caspase-3 during DNA damage-induced apoptosis. Biochemistry 48: 1474-1480, 2009.
41. Shroff EH, Snyder C and Chandel NS: Bcl-2 family members regulate anoxia-induced cell death. Antioxid Redox Signal 9: 1405-1409, 2007.
42. Engelman JA and Jänne PA: Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell Lung cancer. Clin Cancer Res 14: 2895-2899, 2008.
43. Huang S, Benavente S, Armstrong EA, Li C, Wheeler DL and Harari PM: p53 modulates acquired resistance to EGFR inhibitors and radiation. Cancer Res 71: 7071-7079, 2011.
44. Begg AC, Stewart FA and Vens C: Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 11: 239-253, 2011.
45. Chetty C, Bhoopathi P, Rao JS and Lakka SS: Inhibition of matrix metalloproteinase-2 enhances radiosensitivity by abrogating radiation-induced FoxM1-mediated G2/M arrest in A549 lung cancer cells. Int J Cancer 124: 2468-2477, 2009.